跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 3,218 条关于
“EGFR C797S”
全部
3,218
临床试验
1,986
药物
247
机构
1
资讯
984
5天前
BlossomHill's OMNI-EGFR Inhibitor BH-30643 Yields 45% ORR in C797S-Positive NSCLC
4天前
BlossomHill's BH-30643 Hits 45% Response Rate in C797S-Positive NSCLC, Pivotal Phase 2 Planned for Early 2027
去年
BDTX-1535 Shows Promise in Relapsed/Refractory EGFR-Mutant NSCLC
2个月前
BlossomHill Therapeutics Files for $100M Nasdaq IPO to Advance Macrocyclic Cancer Pipeline
去年
Resistance Mechanisms Drive Personalized Treatment Selection After Osimertinib Failure in EGFR-Mutant NSCLC
去年
Pierre Fabre Acquires Global Rights to Next-Generation EGFR Inhibitors for NSCLC Treatment
去年
BlossomHill Therapeutics Advances EGFR-Mutant NSCLC Treatment with First-in-Class OMNI-EGFR Inhibitor BH-30643
去年
Pierre Fabre and Scorpion Therapeutics Initiate Phase I/II Trial of EGFR Inhibitor PFL-241/STX-241 in NSCLC
去年
Novel Treatment Strategies Emerge for EGFR-Mutated NSCLC as Amivantamab Shows Promise
去年
Strategies Emerge to Combat Acquired Resistance in EGFR-Mutant NSCLC
第 1 页,共 99 页
上一页
下一页